Tissue factor pathway inhibitor levels in patients with homocystinuria

Thrombosis Research

Volumn 98, Issue 5, 2000, Pages 375-381

  Cella, Guiseppe ^a   Burlina, Alberto ^a   Sbarai, Alessandra ^a   Motta, Giovanna ^a   Girolami, Antonio ^a   Berrettini, Mauro ^b   Strauss, William ^c  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Section of Cardiology   (United States)

Author keywords

Homocyst(e)ine; Homocystinuria; Thrombosis; Tissue factor pathway inhibitor

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BETAINE; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 7; EPOSCLAR; HEPARIN; PYRIDOXINE; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOMOCYSTINURIA; HUMAN; MALE; PRIORITY JOURNAL; THROMBOSIS; VASCULAR ENDOTHELIUM;

ADULT; BETAINE; BIOLOGICAL MARKERS; CYSTATHIONINE BETA-SYNTHASE; ENDOTHELIUM; FACTOR VII; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HOMOCYSTEINE; HOMOCYSTINURIA; HOMOZYGOTE; HUMANS; LIPOPROTEINS; MALE; PROTEIN C; PYRIDOXINE; SERINE PROTEINASE INHIBITORS; THROMBOMODULIN; THROMBOPLASTIN; VASCULAR DISEASES; VITAMIN B 12;

EID: 0034213789     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00188-2     Document Type: Article

References (34)

1. Mudd S.H., Levy H.L., Skovby F. Disorders of transulfuration. Scriver C.R., Beaudet A.L., Sly W.S., Valle D., Stanbury J.B., Wyngarden J.B., Fredrickson D.S. The metabolic and molecular bases of inherited disease. 1995;1279-1327 McGraw-Hill, New York.
2. Wilcken D.E.L., Wilcken B. The natural history of vascular disease in homocystinuria and the effect of treatment. J Inher Metab Dis. 20:1997;295-300.
3. Mudd S.H., Skovby F., Levy H.L., Pettigrew K.D.E., Wilcken B., Pyeritz R.E., Andria G., Boers G.H.J., Bromberg I.L., Cerone L., Fowler B., Groebe H., Schmidt H., Schweitzer L. The natural history of homocystinuria due to cystationine beta syntase deficiency. Am J Human Genet. 37:1985;1-31.
4. Mandel H., Brenner B., Berant B., Rosenberg N., Lanir N., Jakobs C., Fowler B., Seligsohn U. Coexistence of hereditary homocystinuria and factor V Leiden - Effect on thrombosis. New Engl J Med. 334:1996;763-768.
5. Rees M.M., Rodgers G.M. Homocysteinemia. Association of metabolic disorder with vascular disease and thrombosis Thromb Res. 71:1993;337-359.
6. D'Angelo A., Selhub J. Homocysteine and thrombotic disease. Blood. 90:1997;1-11.
7. Welch G.N., Loscalzo J. Homocysteine and atherothrombosis. New Engl J Med. 338:1998;1042-1045.
8. Simioni P., Prandoni P., Burlina A., Tormene D., Sardella C., Ferrari V., Benedetti L., Girolami A. Hyperhomocystinemia and deep vein thrombosis. Thromb Haemost. 76:1996;883-886.
9. Kojama T., Nishida K., Ohdama S., Sawada M., Murakami N., Hirosawa S., Kurijama R. Matsuzawa K, Hasegawa R, Aoki N. Determination of plasma tissue factor antigen and its clinical significance. Brit J Haemat. 87:1994;343-347.
10. Amiral J., Adam A., Larrivaz I., Chambrette I., Boffa M.C. Design and validation of a new immunoassay for soluble forms of thrombomodulin and studies on plasma. Hybridoma. 13:1994;205-213.
11. Cella G., Cipriani A., Tommasini A., Rampin E., Sbarai A., Rocconi R., Mazzaro G., Luzzatto G. Tissue factor pathway inhibitor antigen plasma level in patients with interstitial lung disease before and after heparin administration. Sem Thromb Hemost. 23:1997;45-49.
12. Bognacki J., Hammelburger J. Functional and immunologic methods for the measurement of the human tissue factor pathway inhibitor. Blood Coagul Fibrinol. 6(Suppl 1):1995;65-72.
13. de Ronde H., Bertina R.M. Laboratory diagnosis of APC-resistance. A critical evaluation of the test and the development of diagnostic criteria Thromb Haemost. 72:1994;880-886.
14. Girolami A., Cattarozzi G., Dal Bo Zanon R., Cella G., Toffanin F. Factor VII Padua2. Another factor VII abnormality with defective ox brain thromboplastin activation and a complex hereditary pattern Blood. 54:1979;46-53.
15. Simioni P., Prandoni P., Lensing A.W., Scudeller A., Sardella C., Prins M.H., Villalta S., Dazzi F., Girolami A. The risk of recurrent venous thromboembolism in patients with an Arg606→Gln mutation in the gene of factor V (factor Leiden). New Engl J Med. 336:1997;399-403.
16. Cella G., Vettor R., Sbarai A., Rossi E., Rampin E., Macor C., Mussap M., Plebani M., Luzzatto G., Girolami A. Endothelial cell-associated tissue factor pathway inhibitor (TFPI) antigen in severe non diabetic obese patients. Effect of hyperinsulinemia. Sem Thromb Hemost. 23:1997;129-134.
17. Celermajer D.S., Sorensen K., Ryalls M., Robinson J., Thomas O., Leonard J.V., Deanfield J.E. Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol. 22:1993;854-858.
18. Mayer E.L., Jacobsen D.W., Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 27:1996;517-527.
19. Rodger G.M., Kane K.W. Activation of endogenous factor V by homocysteine-induced vascular endothelial cell activator. J Clin Invest. 77:1986;1909-1916.
20. Rodger G.M., Conn M.T. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous entothelial cells. Blood. 74:1990;895-901.
21. Harpel P.C., Chang V.T., Broth W. Homocysteine and other sulfhydryl compounds enhance the binding liporotein (a) to fibrin. A potential biochemical link between thrombosis, atherogenesis and sulfhydryl compound metabolism Proc Nat Acad Sci USA. 89:1992;10193-10197.
22. Fryer R.H., Wilson B.D., Gubler D.B., Fitzgerald L.A., Rodger G.M. Homocysteine, a risk factor for vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arter Thromb. 13:1993;1327-1333.
23. Kyrle P.A., Stumpflen A., Hirschl M., Bialonczyk C., Herkner K., Speiser W., Weltermann A., Kaider A., Pabinger I., Lechner K., Eichinger S. Levels of prothrombin fragment F1+2 in patients with hyperhomocysteinemia and a history of venous thromboembolism. Thromb Haemost. 78:1997;1327-1331.
24. de Jong S.C., Stehouwer C.D.A., van den Berg M., Vischer U.M., Rauwerda J.A., Emais J.J. Endothelial marker proteins in hyperhomocysteinemia. Thromb Haemost. 78:1997;1332-1337.
25. Kottke-Marchant K., Green R., Jacobsen D.W., Gupta A., Savon S.R., Secic M., Robinson K. High plasma homocysteine. A risk factor for arterial and venous thrombosis in patients with normal coagulation profiles Clin Appl Thromb/Hemost. 3:1997;239-244.
26. Velasco F., Lopez-Pedrera C., Borrell M., Fontcuberta J., Torres A. Elevated levels of tissue factor pathway inhibitor in acute non-lynophoblastic leukemia patients with disseminated intravascular coagulation. Blood Coagul Fibrinol. 8:1997;70-72.
27. Broze G.J. Jr. Tissue factor pathway inhibitor. Thromb Haemost. 74:1995;90-93.
28. Kokawa T., Enjyoji K.-I., Kumeda K., Kamikubo Y.-I., Harada-Shiba M., Koh I., Tsushima M., Yamamoto A., Kato H. Measurement of the free form of TFPI antigen in hyperlipidemia. Relationship between free and endothelial cell- associated forms of TFPI. Arterioscler Thromb Vasc Biol. 16:1996;802-808.
29. Cella G., Randi M.L. Soluble thrombomodulin as predictor of incident coronary heart disease. Lancet. 354:1999;425.
30. Bauer K.A. Activation of the factor VII-tissue factor pathway. Thromb Haemost. 78:1997;108-111.
31. Palareti G., Salardi S., Piazzi S., Legnani C., Poggi M., Garuso F., Caniato A., Coccheri S., Cacciari E. Blood coagulation changes in homocystinuria. Effects of pyridoxine and other specific therapy J Pediatr. 109:1986;1001-1006.
32. Ratnoff O. Activation of hageman factor by L-homocystine. Science. 162:1968;1007-1009.
33. Tawakol A., Omland T., Gerhard M., Wu J.T., Creager M.A. Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilatation in humans. Circulation. 95:1997;1119-1121.
34. Di Minno G., Davì G., Maraglione M., Cirillo F., Gardone E., Ciabattoni G., Catalano I., Strisciuglio P., Andria G., Patrono C. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Invest. 92:1993;1400-1406.